an important role in blood glucose moderating and there is further research underway. We also know that MNKD has a potentially game changing delivery system for its FDA approved Afreeza.
This is just one example of
clinical trial data with respect to Afreeza’s effectiveness and success. This technology and mode of delivery for many would be preferred over smoking or vaping.
As my deep dive continued, my ongoing investigation led me to a private company called Receptor Life Sciences Inc located in Seatle WA. According to Bloomberg’s section about the company: “Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders”.
I then found an interview featuring MNKD’s CEO, Michael Castagna … and buried in the midst of that interview is our first clue. Here is an exerpt:
Castagna: … A second part in the pipeline is a collaboration called Receptor Life Sciences. That market was focused on the cannabinoid medical-marijuana space, and they'll be looking at a strategy around the 505(b)s [a strategy for gaining approval based on previous clinical data from another entity] for an old product called Marinol. And really, looking at bringing out something going forward in that space for hopefully oncology is what I think the market focus is.
This October 29th, 2018 article titled “Receptor Life Sciences raises $29M, unveils its work on inhaler for medicines based on cannabis” may be an indicator.
This earlier October 2018 article is also of keen interest.
However, the report titled “Research programme: inhaled therapeutics - 9-Tetrahydrocannabinol - MannKind/Receptor Life Sciences; Dronabinol dry powder inhalation – THC” is perhaps the most interesting and revealing.
According to Receptor Life Science’s website:
Our exclusive, patented technologies incorporate years of drug-development research and are validated through their use in FDA-approved products. These technologies will make us the first cannabinoid-focused biopharmaceutical company to offer precision-dosing, high bioavailability and predictable, rapid absorption with every treatment.
Also on Receptor’s website is what appears to resemble a MannKind Corporation Inhaler with the words:
310